{"id":5010,"date":"2024-06-28T14:45:27","date_gmt":"2024-06-28T14:45:27","guid":{"rendered":"https:\/\/regtechafrica.com\/healthcare\/?p=5010"},"modified":"2024-06-28T14:45:27","modified_gmt":"2024-06-28T14:45:27","slug":"global-fda-declines-approval-for-merck-daiichis-targeted-lung-cancer-therapy","status":"publish","type":"post","link":"https:\/\/regtechafrica.com\/healthcare\/global-fda-declines-approval-for-merck-daiichis-targeted-lung-cancer-therapy\/","title":{"rendered":"Global: FDA Declines Approval for Merck-Daiichi&#8217;s Targeted Lung Cancer Therapy"},"content":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) has declined to approve Merck and Japan-based Daiichi Sankyo&#8217;s lung cancer treatment, patritumab deruxtecan, which belongs to a class of cancer therapies known as &#8220;guided missiles&#8221;. This decision, communicated through a complete response letter issued late on Wednesday, follows findings from an inspection of a third-party manufacturing facility.<\/p>\n<p>In the letter, the FDA highlighted outstanding questions related to the manufacturing process but did not raise concerns regarding the treatment&#8217;s efficacy or safety data submitted by the companies. Merck and Daiichi Sankyo have committed to collaborating closely with the FDA and the third-party manufacturer to address these issues.<\/p>\n<p>Patritumab deruxtecan is an antibody-drug conjugate (ADC), designed to specifically target tumor cells with minimal impact on healthy tissues, akin to a &#8220;guided missile&#8221;. The therapy was intended for the treatment of non-small cell lung cancer in patients who have not responded to two prior lines of therapy and whose tumors express a particular mutation leading to uncontrolled growth of the EGFR protein.<\/p>\n<p>This setback comes despite Merck and Daiichi Sankyo&#8217;s joint efforts under a significant up to $22-billion development and commercialization agreement signed last year, focusing on innovative cancer treatments. Currently, treatments like Johnson &amp; Johnson&#8217;s Rybrevant and AstraZeneca&#8217;s Tagrisso and Iressa are approved in the U.S. for EGFR-mutated non-small cell lung cancer.<\/p>\n<p>The companies remain committed to advancing patritumab deruxtecan and will continue to work closely with regulatory authorities to address the FDA&#8217;s concerns and potentially bring this promising therapy to patients in need.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) has declined to approve Merck and Japan-based Daiichi Sankyo&#8217;s lung cancer treatment, patritumab deruxtecan, which belongs to a class of cancer therapies known&hellip;<\/p>\n","protected":false},"author":1,"featured_media":5013,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[78],"tags":[],"class_list":["post-5010","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-regulatory"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/regtechafrica.com\/healthcare\/wp-content\/uploads\/2024\/06\/FDA-Declines-Approval-for-Merck-Daiichis-Targeted-Lung-Cancer-Therapy.jpg?fit=1920%2C1080&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts\/5010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/comments?post=5010"}],"version-history":[{"count":1,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts\/5010\/revisions"}],"predecessor-version":[{"id":5014,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts\/5010\/revisions\/5014"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/media\/5013"}],"wp:attachment":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/media?parent=5010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/categories?post=5010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/tags?post=5010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}